Abstract:There is an urgent unmet need for robust and reliable biomarkers for early diagnosis, prognosis, and prediction of response to specific treatments of many aggressive and deadly cancers, such as pancreatic cancer, and liquid biopsy-based miRNA profiling has the potential for this. MiRNAs are a subset of non-coding RNAs that regulate the expression of a multitude of genes post-transcriptionally and thus are potential diagnostic, prognostic, and predictive biomarkers and have also emerged as potential therapeutics. Because miRNAs are involved in the post-transcriptional regulation of their target mRNAs via repressing gene expression, defects in miRNA biogenesis pathway and miRNA expression perturb the expression of a multitude of oncogenic or tumor-suppressive genes that are involved in the pathogenesis of various cancers. As such, numerous miRNAs have been identified to be downregulated or upregulated in many cancers, functioning as either oncomes or oncosuppressor miRs. Moreover, dysregulation of miRNA biogenesis pathways can also change miRNA expression and function in cancer. Profiling of dysregulated miRNAs in pancreatic cancer has been shown to correlate with disease diagnosis, indicate optimal treatment options and predict response to a specific therapy. Specific miRNA signatures can track the stages of pancreatic cancer and hold potential as diagnostic, prognostic, and predictive markers, as well as therapeutics such as miRNA mimics and miRNA inhibitors (antagomirs). Furthermore, identified specific miRNAs and genes they regulate in pancreatic cancer along with downstream pathways can be used as potential therapeutic targets. However, a limited understanding and validation of the specific roles of miRNAs, lack of tissue specificity, methodological, technical, or analytical reproducibility, harmonization of miRNA isolation and quantification methods, the use of standard operating procedures, and the availability of automated and standardized assays to improve reproducibility between independent studies limit bench-to-bedside translation of the miRNA biomarkers for clinical applications. Here I review recent findings on miRNAs in pancreatic cancer pathogenesis and their potential as diagnostic, prognostic, and predictive markers.

miRNAs: Potential as Biomarkers and Therapeutic Targets for Cancer

Molecular Mechanisms and Clinical Applications of Mir-22 in Regulating Malignant Progression in Human Cancer (Review)

MicroRNAs As Potential Biomarkers in Cancer: Opportunities and Challenges

miRNA-based biomarkers, therapies, and resistance in Cancer

MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future?

Exploring the role of microRNAs as diagnostic and prognostic biomarkers in canine mammary tumors

Exploiting the therapeutic potential of microRNAs in human cancer

MiRNAs and Cancer: Key Link in Diagnosis and Therapy

MicroRNAs and Cancer: Key Paradigms in Molecular Therapy (Review)

MicroRNAs in Colorectal Cancer As Markers and Targets: Recent Advances.

microRNA:A new cancer biomarker

Potential Microrna Targets For Cancer Chemotherapy

miRNA on the Battlefield of Cancer: Significance in Cancer Stem Cells, WNT Pathway, and Treatment

The roles of miRNAs in human breast cancer and canine mammary tumor

Altered microRNA Expression Profiles and Regulation of INK4A/CDKN2A Tumor Suppressor Genes in Canine Breast Cancer Models

MiRNAs in Human Cancers: the Diagnostic and Therapeutic Implications

miRNA: A Promising Therapeutic Target in Cancer

Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges

Role of miRNAs in breast cancer development and progression: Current research

microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer

MicroRNAs: emerging biomarkers and therapeutic targets in pancreatic cancer